Leerink Partners analyst David Risinger maintained a Buy rating on Sanofi on July 7 and set a price target of €101.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
David Risinger has given his Buy rating due to a combination of factors that highlight Sanofi’s potential for future growth despite some recent challenges. Risinger acknowledges the reduction in the price target from €115 to €101, reflecting a more conservative outlook on Sanofi’s earnings growth over the next five years. This adjustment comes after revising the company’s research and development expenses and foreign exchange assumptions, which impacted the earnings per share projections for 2025.
Despite these adjustments, Risinger remains optimistic about Sanofi’s prospects, particularly due to the strong performance of Dupixent. The drug has shown accelerated growth in the U.S., supported by recent FDA approvals for new indications, which suggests a durable revenue stream. Furthermore, the extension of Dupixent’s patent protection in the U.S. provides a significant competitive advantage, potentially safeguarding it from biosimilar competition. These factors contribute to Risinger’s confidence in maintaining a Buy rating for Sanofi’s stock.
In another report released yesterday, UBS also maintained a Buy rating on the stock with a €115.00 price target.